Daniel Tassé is no longer serving in their board position at Alcresta Therapeutics, Inc.
Jan 31, 2019
Board and Executive Moves
Chief Executive Officer & Executive Director at DBV Technologies
Alcresta Therapeutics, Inc. engages in the development of enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. It offers products designed to improve the delivery, digestion, and absorption of long-chain polyunsaturated fatty acids or LCPUFAs. The company was founded by Robert Gallotto and Dr. Alexey L. Margolin in 2011 and is headquartered in Newton, MA.